Treatment with Gleevec and other kinase inhibitors at Dana-Farber
A new class of cancer drugs known as kinase inhibitors, which includes Gleevec, has been a welcome addition to treatment for people with two rare cancers: Chronic Myeloid Leukemia (CML) and the sarcoma known as Gastrointestinal Stromal Tumor (GIST). Unlike standard chemotherapy, kinase inhibitors block a very specific cancer mechanism in cells, and have fewer side effects than chemotherapy. In addition, they are given orally in pill form.
Physicians at Dana-Farber Cancer Institute are prescribing kinase inhibitors for CML patients in certain stages of the disease, and in clinical trials for people with specific types of GIST, high-grade brain tumors, acute myeloid leukemia (AML), kidney cancer, prostate cancer, and neuroendocrine tumors.
Contact Information
For those interested in becoming a patient at Dana-Farber who would like to learn more about the Institute?s use of kinase inhibitors such as Gleevec, please contact the following numbers:
Leukemia: (617) 632-5138
GIST/Sarcoma: (617) 632-5122
Brain tumors: (617) 632-2166
Neuroendocrine tumors: (617) 632-3476
Kidney cancer: (617) 632-3466
Prostate cancer: (617) 632-3466
DF/PCC clinical trials with Gleevec and other kinase inhibitors
Some of the trials listed below may be closed to new patients, even if they aren't labeled as such. To learn more about these trials, please call our clinical trials service at (866) 790-4500 or visit our clinical trials page.
GIST
Phase II trial of neoadjuvant/adjuvant STI-571 (Gleevec) for primary and recurrent operable malignant GIST expressing the Kit receptor tyrosine kinase (CD117) (#01292)
Phase III randomized double blind study of adjuvant STI-571 (Gleevec) versus placebo in patients following the complete resection of primary GastroIntestinal Stromal Tumor (#02190)
Phase III study of SUO11248 for malignant GIST (#03288)
Open label, pilot phase II study of STI-571 (Gleevec) in patients with life threatening diseases known to be associated with one or more STI-571-sensitive tyrosine kinases (#01064) Closed to New Patients
Phase III trial of STI-571 (Gleevec) for patients with unresectable or metastatic GIST (#01015) Closed to New Patients
Randomized phase II study of STI-571 (Gleevec) in patients with unresectable or metastatic GIST (#00113) Closed to New Patients
Phase I study of SU011248 in the treatment of patients with malignant GIST who are intolerant of, or with disease progression on, Imatinib Mesylate (Gleevec) (#02037) Closed to New Patients
Brain tumors
Phase I-II Trial of STI-571 (Gleevec) in patients with recurrent malignant gliomas (#00298)
Phase II Trial of STI-571 (Gleevec) in patients with recurrent meningioma (#03048)
Neuroendocrine tumors
Phase II study of the efficacy and safety of SU011248 in patients with advanced unresectable neuroendocrine tumor (#02317)
Acute Myeloid Leukemia (AML)
Phase I/II tolerability and PK/PD of multiple oral doses of CT53518 in patients with acute myelogenous leukemia (#02038)
Open-label, randomized phase II trial of PKC 412 monotherapy in patients with acute myeloid leukemia (AML) and patients with high risk myelodysplastic syndrome (MDS) with either wild type or mutated FLT3 (#03112)
Chronic Myeloid Leukemia (CML)
Phase II, open label study to determine the safety and anti-leukemic effects of STI-571 (Gleevec) in adult patients with chronic myeloid leukemia in myeloid blast crisis (#99208) Closed to New Patients
Phase II study to determine the efficacy and safety of STI571 (Gleevec) in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha (#99313) Closed to New Patients
Prostate cancer
Pilot study of orally administered STI-571 (Gleevec) prior to radical prostatectomy in patients with newly diagnosed prostate cancer (#01172) Closed to New Patients
NCI Clinical Trials with Gleevec and other kinase inhibitors
To learn more about kinase inhibitor trials taking place at other hospitals around the U.S., please call our clinical trials service at (866) 790-4500 or search our NCI database.
Related Stories and Press Releases
Study finds new designer drug is potent treatment for chronic myelogenous leukemia (Feb. 14, 2005) read more
Clinical trial shows SU11248 benefits more than half of patients with gastrointestinal tumors resistant to Gleevec (June 8, 2004) read more
Study identifies which patients can benefit from targeted lung cancer drug - and why (April 29, 2004) read more
The kinase race (Paths of Progress, Fall/Winter 2003) read more
Test shows who'll respond to Gleevec (Dec.3, 2003) read more
New compound shows promise when Gleevec loses potency in patients with rare digestive-tract cancer (June 4, 2003) read more
Joint study on protein-cancer connection underscores promise of targeted therapies (Jan. 22, 2003) read more
"Designer" drug shows activity in leukemia (Dec. 9, 2002) read more
Gleevec shrinks tumors in over half of patients with incurable stomach cancer (Aug. 19, 2002) read more
FDA approves Gleevec as oral treatment for Gastrointestinal Stromal Cancer (Feb. 1, 2002) read more
"Gleevec: The Dana-Farber connection" (Paths of Progress, Fall/Winter 2001) read more
New drug dissolves stomach tumors (May 14, 2001) read more
International Collaboration Announces Results of Gleevec
Trial for Rare Form of Abdominal Cancer Known as GIST (April 14, 2001)
read more
Oral therapy for leukemia [Gleevec] can treat an otherwise
incurable form of abdominal cancer [GIST] (April 4, 2001)
read more
(Information last updated on June 17, 2004)
